立他司特（Lifitegrast）是一種新的細(xì)胞間黏附因子的抑制劑，可以通過阻斷細(xì)胞間黏附分子-1和整合素蛋白淋巴細(xì)胞功能相關(guān)抗原-1之間的結(jié)合起效。2016年7月，美國(guó)食品藥品管理局（FDA）正式批準(zhǔn)了5%立他司特滴眼劑（商品名Xiidra^TM）的申請(qǐng)。該藥的臨床試驗(yàn)主要包括針對(duì)干眼癥患者的1個(gè)為期12周的II期臨床試驗(yàn)和3個(gè)為期12周的III期臨床試驗(yàn)，研究結(jié)果充分證明了該藥的有效性和安全性。立他司特是FDA批準(zhǔn)的第一個(gè)可以改善和治療干眼癥癥狀的新藥，其他類似藥物只有環(huán)孢素，在不久的將來(lái)其臨床應(yīng)用會(huì)更加廣泛。

Lifitegrast is a novel inhibitor of integrin, which can take effect by blocking the binding of intercellular adhesion molecule 1 and integrin lymphocyte function associated antigen 1. In July 2016, the U.S. Food and Drug Administration (FDA) officially approved the application of lifitegrast ophthalmic solution 5% (commodity name Xiidra^TM). Clinical trials of the drug include a 12-week phase II clinical trial and three 12-week phase III clinical trials for dry eye disease patients. The results of clinical trials have demonstrated the efficacy and safety of the drug. Lifitegrast is the first FDA approved drug to improve and treat dry eye symptoms, and other similar drug is only cyclosporine. It is believed that in the near future clinical application of lifitegrast will be more extensive.